Table 5.
Self-reported side effects and injection-site reactions (ISR) by self-injected DMPA-SC and provider-injected DMPA-IM users in Senegal
| After 1st injection |
After 2nd injection |
After 3rd injection |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Self-injected DMPA-SC (n=649) | Provider-injected DMPA-IM (n=642) | p value | Self-injected DMPA-SC (n=615) | Provider-injected DMPA-IM (n=598) | p value | Self-injected DMPA-SC (n=588) | Provider-injected DMPA-IM (n=559) | p value | |
| Experienced side effects | 195 (30.1) | 227 (35.4) | .04 | 130 (21.1) | 155 (25.9) | .05 | 102 (17.4) | 125 (22.4) | .03 |
| Sought treatment | 18/195 (9.2) | 50/227 (22.0) | .00 | 17/130 (13.1) | 32/155 (20.6) | .09 | 16/102 (15.7) | 28/125 (22.4) | .20 |
| Experienced ISR | 89 (13.7) | 63 (9.8) | .03 | 52 (8.5) | 55 (9.2) | .65 | 29 (4.9) | 30 (5.4) | .74 |
| Sought ISR treatment | 0/89 (0.0) | 0/63 (0.0) | - | 0/52 (0.0) | 0/55 (0.0) | - | 0/29 (0.0) | 1/30 (3.3) | .32 |